Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth
Authors:
Open Access
- 26 February 2019
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 8 (3) , 1-12
Abstract
Despite a growing body of knowledge about the genomic landscape and molecular pathogenesis of sarcomas, translation of basic discoveries into targeted therapies and significant clinical gains has remained elusive. Renewed interest in altered metabolic properties of cancer cells has led to an exploration of targeting metabolic dependencies as a novel therapeutic strategy. In this study, we have characterized the dependency of human pediatric sarcoma cells on key metabolic substrates and identified a mechanism of adaptation to metabolic stress by examining proliferation and bioenergetic properties of rhabdomyosarcoma and Ewing sarcoma cells under varying concentrations of glucose and glutamine. While all cell lines tested were completely growth-inhibited by lack of glucose, cells adapted to glutamine deprivation, and restored proliferation following an initial period of reduced growth. We show that expression of glutamine synthetase (GS), the enzyme responsible for de novo glutamine synthesis, increased during glutamine deprivation, and that pharmacological or shRNA-mediated GS inhibition abolished proliferation of glutamine-deprived cells, while having no effect on cells grown under normal culture conditions. Moreover, the GS substrates and glutamine precursors glutamate and ammonia restored proliferation of glutamine-deprived cells in a GS-dependent manner, further emphasizing the necessity of GS for adaptation to glutamine stress. Furthermore, pharmacological and shRNA-mediated GS inhibition significantly reduced orthotopic xenograft tumor growth. We also show that glutamine supports sarcoma nucleotide biosynthesis and optimal mitochondrial bioenergetics. Our findings demonstrate that GS mediates proliferation of glutamine-deprived pediatric sarcomas, and suggest that targeting metabolic dependencies of sarcomas should be further investigated as a potential therapeutic strategy.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 40 references indexed in Scilit:
- Prospects and challenges for the development of new therapies for Ewing sarcomaPharmacology & Therapeutics, 2012
- The Epidemiology of SarcomaClinical Sarcoma Research, 2012
- Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric RhabdomyosarcomaClinical Nuclear Medicine, 2011
- Advances in sarcoma genomics and new therapeutic targetsNature Reviews Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Receptor Tyrosine Kinases as Therapeutic Targets in RhabdomyosarcomaSarcoma, 2011
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and ProliferationCell Metabolism, 2008
- Mechanisms of sarcoma developmentNature Reviews Cancer, 2003
- Structure–function relationships of glutamine synthetasesBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000